(dna Communications) Celgene Corporation and bluebird bio announce results from ongoing multicenter Phase 1 study of bb2121 anti-BCMA CAR T cell therapy in patients with multiple myeloma published in the New England Journal of Medicine.
Original Article: NEJM publishes bb2121 Phase 1 data in patients with multiple myeloma